D a t a e x t r a c t i o n
Data were extracted on setting; country; dose, duration, and follow-up of treatment; number of participants and demographics; assessment of comorbid disease; follow-up losses; adverse effects; and outcomes. Methodologic quality of individual trials was assessed using the Jadad scale.
M a i n r e s u l t s 13 trials (mean sample size 54, mean duration 8.1 wk) were included in the analysis. Mean quality score for the Jadad scale was 5.6 out of 8. Nine studies did not state the method of randomization, 7 had no intention-to-treat analysis, 3 had inadequate assurance of blinding effectiveness, 5 had no assessment of adverse effects, and 6 had > 20% loss to follow-up. Trials assessed the efficacy of 3 classes of antidepressants: tricyclics (8 trials of amitriptyline, 1 of clomipramine, and 1 of maprotiline); S-adenosylmethionine (2 trials); and selective serotonin reuptake inhibitors (2 of fluoxetine and 1 of citalopram). Meta-analysis was done using a random-effects model. Metaanalysis of dichotomous outcome data (10 trials) showed that patients who received antidepressants had more symptom improvement than did those who received placebo (odds ratio 4.2, 95% CI 2.6 to 6.8; number needed to treat 4, CI 2.9 to 6.3). Meta-analysis of continuous outcome data showed that antidepressants were associated with improvements in fatigue scores (8 trials, 0.39 SD unit improvement, CI 0.11 to 0.66), sleep scores (8 trials, 0.49 SD unit improvement, CI 0.3 to 0.69), pain scores (10 trials, 0.52 SD unit improvement, CI 0.21 to 0.81), and overall well-being (7 trials, 0.49 SD unit improvement, CI 0.18 to 0.80) but not in the number of trigger points.
C o n c l u s i o n
Antidepressants improve overall symptoms and individual symptoms of fatigue, sleep, and pain in fibromyalgia. 
C o m m e n t a r y
O'Malley and colleagues did a systematic review of 13 randomized, placebo-controlled trials that included ≥ 1 medication arm with an antidepressant, usually a tricyclic. Analysis showed heterogeneous effect sizes for pain, well-being, sleep, fatigue, and number of trigger points (also called tender points). Summary effect sizes of the 4 self-reported measurements were statistically significant and showed a moderate treatment effect. The physician-reported number of tender points did not differ by treatment group. As the authors state, however, adequate blinding in trials was difficult because of the side effects of antidepressants. Moreover, the authors found statistical evidence for publication bias. The results from the 13 articles were probably analyzed by dichotomous classification in favor of the antidepressant or placebo, a classification based on statistical rather than clinical relevance. The authors presented the results in terms of odds ratios and numbers needed to treat (NNTs). This representation of results is difficult to interpret.
The authors conclude that antidepressants are effective for fibromyalgia. This conclusion appears too strong from both the methodologic and the clinical perspectives. Heterogeneity of results between (and undoubtedly also within) studies suggests that antidepressants are moderately effective in only some patients. Another meta-analysis of 49 studies assessed the efficacy of pharmacologic and nonpharmacologic interventions for fibromyalgia (1) . In this review, exercise and cognitive behavioral therapy were more efficacious than pharmacologic treatment alone for self-reported fibromyalgia symptoms. A similar trend was observed for functional measurements. These findings suggest that the treatment of choice in fibromyalgia is daily physical exercise and encouragement of positive behavior. Rather than analyzing the effects of pharmacologic treatments per se, the objective of future evaluations should be to determine which patients profit from antidepressants as adjuncts to nonpharmacologic interventions and which antidepressants perform best.
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